[go: up one dir, main page]

WO2000012556A1 - Anticorps a forte affinite - Google Patents

Anticorps a forte affinite Download PDF

Info

Publication number
WO2000012556A1
WO2000012556A1 PCT/GB1999/002729 GB9902729W WO0012556A1 WO 2000012556 A1 WO2000012556 A1 WO 2000012556A1 GB 9902729 W GB9902729 W GB 9902729W WO 0012556 A1 WO0012556 A1 WO 0012556A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
samples
sample
hour
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1999/002729
Other languages
English (en)
Inventor
Peter John Harrison
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KS Biomedix Ltd
Original Assignee
KS Biomedix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2000571062A priority Critical patent/JP2002525082A/ja
Priority to PL99346472A priority patent/PL346472A1/xx
Priority to EA200100287A priority patent/EA200100287A1/ru
Priority to BR9913303-2A priority patent/BR9913303A/pt
Priority to MXPA01002248A priority patent/MXPA01002248A/es
Priority to EP99940355A priority patent/EP1107990A1/fr
Priority to HR20010149A priority patent/HRP20010149A2/hr
Priority to HU0103233A priority patent/HUP0103233A3/hu
Priority to AU54350/99A priority patent/AU5435099A/en
Application filed by KS Biomedix Ltd filed Critical KS Biomedix Ltd
Priority to KR1020017002434A priority patent/KR20010089174A/ko
Priority to CA002340865A priority patent/CA2340865A1/fr
Priority to IL14152399A priority patent/IL141523A0/xx
Publication of WO2000012556A1 publication Critical patent/WO2000012556A1/fr
Priority to BG105294A priority patent/BG105294A/bg
Priority to NO20011006A priority patent/NO20011006L/no
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Definitions

  • This invention relates to antibodies and their therapeutic use. Background to the Invention
  • Antibodies have long been regarded as potentially powerful tools in the treatment of cancer and other diseases. However, although there have been some notable exceptions, this potential has not generally yet been realised.
  • a high-affinity antibody has affinity characterised by:
  • the maximum pH in step (iii) is 2.5, more preferably 2.0.
  • Antibodies or antibody fragments with the "acid- resistant" properties are expected to favour association rather than dissociation and they therefore have longer localisation times at target sites, which results in a higher concentration of antibodies localised at the target sites.
  • this invention relates to the production of a high affinity single-chain Fv antibody fragment.
  • This ScFv has particular advantages in that it allows better targeting to a site in vivo . Description of the Drawing
  • Figure 1 illustrates the results achieved for acid- resistance of sheep and mouse monoclonal antibodies and single-chain Fvs with affinity to carcinoembryonic antigen at various pH values. Description of the Invention
  • the acid-resistant monoclonal antibodies according to the present invention may be obtained using various techniques. For example, classical hybridoma technology can be applied, comprising the fusion of B-lymphocytes from immunised animals secreting high-affinity antibodies with an appropriate fusion partner.
  • An alternative method is to purify the mRNA from selected lymphocytes and use the technique of PCR to amplify the antibody genes required.
  • Phage display technology and other techniques for the display of antibody fragments may also be used to obtain the antibody genes from naive or immunised libraries after appropriate selection procedures.
  • the antibody gene can be co-expressed with or otherwise chemically linked to toxins, radioisotopes or enzymes or any other desirable molecules to provide a fusion protein with strong binding characteristics.
  • the antibodies may be produced by transgenic animals as described in US-A-5770429.
  • the antibody may be a whole antibody, comprising heavy and light chains, and constant and variable regions.
  • the antibody is an antibody fragment, e.g. F(ab') 2.
  • Fab, Fv or single-chain Fv fragments provided that at least part of the variable region is present which confers the property of "acid resistance”.
  • the antibody may also be an animal, chimeric or humanised antibody. A suitable method for producing humanised antibodies is disclosed in O-A-92/15699.
  • the antibody is a single-chain Fv fragment.
  • the single-chain Fv fragment comprises both heavy chain and light chain variable regions linked by a suitable peptide.
  • the antibodies of the present invention may be defined by their acid-resistant properties, which can be characterised by an acid-washed enzyme-linked im unosorbent assay (EIA) , as described above.
  • EIA enzyme-linked im unosorbent assay
  • the A 405 value obtained by EIA will represent antibody binding of >50% for a sample at pH 3 or below, compared to the value for the sample at pH 7.2.
  • the A 40s value of a sample at pH 2 will represent antibody binding of >60% more preferably 70% of that obtained at pH 7.2.
  • the animal that is subjected to immunisation is not a rodent, but is chosen to give higher affinity antibodies. Any large mammal may be used and suitable animals include rabbits, goats, cows and sheep.
  • An antibody of the invention may be used in therapy and may be formulated into any suitable composition with a physiologically-acceptable excipient, diluent or carrier. The following Examples illustrate the invention. Example 1.
  • CEA carcinoembryonic antigen
  • lymph node cells were then washed and fused with sheep heteromyeloma fusion partner SFP3.2. Fused cells were plated out at a total density of approximately 10 b per ml in medium containing HAT (Life Technologies) . These samples were then screened for hybridomas secreting high- affinity antibodies to the specified antigen using both a normal EIA and an acid-washed EIA.
  • Standard EIA screening assays were carried out as follows: Maxisorb assay plates (NUNC) were coated with CEA (0.4 ⁇ g/ml in phosphate-buffered saline at pH 7.2), lOO ⁇ l per well and left overnight at 4°C. The plates were then washed three times using phosphate buffered saline at pH 7.2 with 0.01% Tween 20 detergent. Any remaining reactive sites on the plates were blocked by the addition of 200 ⁇ l per well of 0.2% fat-free milk protein in PBS at pH 7.2 at 37°C for hour. The plates were then washed in PBS as described above and 45 ⁇ l of the antibody samples were added to the wells of the plates.
  • Example 2 A single-chain Fv fragment was produced from the hybridoma 6H9 above, as follows: mRNA was purified from the cultured hybridoma cells using oligo-dT cellulose. Single-stranded DNA complementary to the mRNA (cDNA) was synthesized by reverse transcription. Universal primers, designed from the constant regions of sheep heavy and light chain antibody genes, were used in separate reverse transcription reactions to synthesise the cDNA for the antibody variable regions.
  • the cDNA was then amplified by the polymerase chain reaction to make double-stranded DNA using primers designed from the heavy and light chain variable framework sequences. Separate polymerase chain reactions were used to amplify the heavy and light chain regions. The products were then analysed by agarose gel electrophoresis and the DNA bands equivalent to light and heavy chain genes were cut from the gel and purified. Equi olar amounts of variable heavy and light chain DNA were mixed together with an oligonucleotide linker DNA. The linker DNA coded for the amino acid sequence (Gly 4 Ser) 3 with additional nucleotides complementary to the 3 ' end of the heavy chain variable region and the 5' end of the light chain variable region. The three DNA molecules were denatured, annealed and extended in the first stage (without primers) of a two-stage PCR reaction so that the fragments were joined, thereby assembling the single-chain Fv.
  • the single-chain Fv DNA was amplified in the second stage of the PCR using a pair of primers derived from the heavy and light chain variable region termini with the addition of the restriction enzyme recognition sites for A1W44 ⁇ and Notl .
  • the single-chain Fv gene product was analysed by agarose gel electrophoresis and purified.
  • the single-chain Fv was then digested with the restriction enzymes AlW44 i and Notl and cloned into an expression vector.
  • the vector was then used to transform E . coli HB 2151, and protein expression was allowed to occur.
  • the vector was designed so as to include a hexa-histidine tag at the COOH terminus of the SFv.
  • the single-chain Fv was purified using nickel-chelate affinity chromatography and analysed by SDS-PAGE.
  • the amino acid sequence for the heavy chain variable region and the light chain variable region is disclosed in SEQ ID Nos. 2 and 4, respectively.
  • An acid-wash EIA was also carried out to determine the acid-resistant properties of the single-chain Fv.
  • Acid-wash EIA was carried out as follows: Carcinoembryonic antigen (CEA) -coated microtitre plates were prepared as described previously.
  • Single-chain Fv samples (6H9) were diluted to a range of concentrations between lng/ml and lOOng/ml in PBS at pH 7.2 containing 1% bovine serum albumin (BSA) .
  • BSA bovine serum albumin
  • lOO ⁇ l samples were added to the microtitre plate wells and incubated for 1 hour at 37°C.
  • the plates were then washed, 200 ⁇ l per well of citrate added, and the plates incubated for 1 hour at 37°C.
  • the acid preparations were made using a stock solution of lOOmM citrate diluted to pH values of 4.0, 3.5, 3.0, 2.5 and 2.0 in the reaction mixture. PBS at pH 7.2 was used as a reference control.
  • the plates were then washed and lOO ⁇ l per well of mouse anti-tetra-histidine antibody (Qiagen) (lOOng/ml diluted in PBS at pH 7.2 with 1% BSA) added and incubated for 1 hour at 37°C.
  • Qiagen mouse anti-tetra-histidine antibody
  • sFv samples were incubated with PBS at pH 7.2 to generate an EIA response curve for the SFv samples.
  • a concentration of 10-20ng/ml of the SFv sample gave an absorbance (A 405 ) of 1.0-1.5 and was therefore used to determine the amount of antibody bound in the acid washed samples as a percentage of the amount bound in the reference sample.
  • the acid-resistant properties of the 6H9 whole antibody and the 6H9 single-chain Fv were compared with that for the mouse-derived anti-carcinoembryonic antigen whole antibody, A5B7 and the single-chain Fv MFE.
  • the results are shown in Figure 1, with the antigen-binding of the mouse-derived antibodies being substantially reduced at pH 3.5 and less than 5% at pH 2.5.
  • the 6H9 antibodies retain >70% antigen at pH 3.5, >60% at pH 2.5 and >50% at pH 2.0.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Cette invention se rapporte à des anticorps monoclonaux à forte affinité, cette affinité se caractérisant par les opérations suivantes: (i) on laisse incuber un premier et un second échantillon de l'anticorps dans les alvéoles d'une plaque de microtitration recouverte d'antigène, à une concentration choisie de façon à se situer dans la partie linéaire d'une courbe standard à un pH de 7,2 pendant 1 heure à 37 °C; (ii) on retire des deux échantillons tout anticorps non lié; (iii) on laisse incuber le premier échantillon avec un soluté tampon de phosphate à un pH de 7,2 pendant une heure à 37 °C, et on abaisse le pH du second échantillon jusqu'à atteindre un pH égal ou inférieur à 3, et on laisse incuber ce premier échantillon pendant 1 heure à 37 °C; (iv) on retire des deux échantillons tout anticorps non lié; (v) on laisse incuber les deux échantillons avec un conjugué de phosphatase alcaline anti-anticorps pendant 1 heure à 37 °C; Cvi) on retire des deux échantillons tout conjugué non lié; et (vii) on ajoute aux échantillon sun substrat PNPP, on mesure l'absorbance des échantillons à 405nm et on détermine la quantité d'anticorps liée à l'antigène, la quantité liée du second échantillon constituant plus de 50 % de celle du premier échantillon.
PCT/GB1999/002729 1998-08-28 1999-08-20 Anticorps a forte affinite Ceased WO2000012556A1 (fr)

Priority Applications (14)

Application Number Priority Date Filing Date Title
AU54350/99A AU5435099A (en) 1998-08-28 1999-08-20 High-affinity antibodies
EA200100287A EA200100287A1 (ru) 1998-08-28 1999-08-20 Высокоаффинные антитела
BR9913303-2A BR9913303A (pt) 1998-08-28 1999-08-20 Anticorpos de alta afinidade
MXPA01002248A MXPA01002248A (es) 1998-08-28 1999-08-20 Anticuerpos de alta afinidad.
EP99940355A EP1107990A1 (fr) 1998-08-28 1999-08-20 Anticorps a forte affinite
HR20010149A HRP20010149A2 (en) 1998-08-28 1999-08-20 High-affinity antibodies
HU0103233A HUP0103233A3 (en) 1998-08-28 1999-08-20 High-affinity antibodies
JP2000571062A JP2002525082A (ja) 1998-08-28 1999-08-20 高親和性抗体
KR1020017002434A KR20010089174A (ko) 1998-08-28 1999-08-20 고친화성 항체
PL99346472A PL346472A1 (en) 1998-08-28 1999-08-20 High-affinity antibodies
CA002340865A CA2340865A1 (fr) 1998-08-28 1999-08-20 Anticorps a forte affinite
IL14152399A IL141523A0 (en) 1998-08-28 1999-08-20 High-affinity antibodies
BG105294A BG105294A (bg) 1998-08-28 2001-02-26 Високоафинитетни антитела
NO20011006A NO20011006L (no) 1998-08-28 2001-02-27 Höy-affinitets antistoffer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9818915.2 1998-08-28
GBGB9818915.2A GB9818915D0 (en) 1998-08-28 1998-08-28 Antibodies

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09786015 A-371-Of-International 2001-04-09
US10/199,908 Division US20030008355A1 (en) 1998-08-28 2002-07-18 High-affinity antibodies

Publications (1)

Publication Number Publication Date
WO2000012556A1 true WO2000012556A1 (fr) 2000-03-09

Family

ID=10838074

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/002729 Ceased WO2000012556A1 (fr) 1998-08-28 1999-08-20 Anticorps a forte affinite

Country Status (21)

Country Link
EP (1) EP1107990A1 (fr)
JP (1) JP2002525082A (fr)
KR (1) KR20010089174A (fr)
CN (1) CN1315966A (fr)
AU (1) AU5435099A (fr)
BG (1) BG105294A (fr)
BR (1) BR9913303A (fr)
CA (1) CA2340865A1 (fr)
EA (1) EA200100287A1 (fr)
GB (1) GB9818915D0 (fr)
HR (1) HRP20010149A2 (fr)
HU (1) HUP0103233A3 (fr)
ID (1) ID28905A (fr)
IL (1) IL141523A0 (fr)
MX (1) MXPA01002248A (fr)
NO (1) NO20011006L (fr)
PL (1) PL346472A1 (fr)
TR (1) TR200100643T2 (fr)
WO (1) WO2000012556A1 (fr)
YU (1) YU15401A (fr)
ZA (1) ZA200101573B (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002096437A1 (fr) * 2001-05-25 2002-12-05 Psimei Pharmaceuticals Plc Therapie par capture de neutrons
WO2002050120A3 (fr) * 2000-12-21 2003-04-24 Ks Biomedix Holdings Plc Anticorps hautement affinitaires
JP2005529612A (ja) * 2002-06-12 2005-10-06 バイエル・ヘルスケア・エルエルシー 糖化した標識の結合による細菌検査法
EP1511861A4 (fr) * 2002-06-12 2007-12-05 Genencor Int Methodes et compositions de liaison dependant du milieu d'un agent cible a une cible

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1691763A4 (fr) * 2003-12-12 2008-03-12 Genencor Int Molecules cab
CN111848790B (zh) * 2020-08-07 2022-02-22 上海交通大学 一种牛源抗金黄色葡萄球菌的单链抗体及其制备和应用
CN112724255A (zh) * 2021-01-28 2021-04-30 成都金昆生物科技有限公司 靶向癌胚抗原的小分子抗体

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991001990A1 (fr) * 1989-07-26 1991-02-21 City Of Hope Anticorps chimerique anti-antigene carcinoembryonique
WO1992001059A1 (fr) * 1990-07-05 1992-01-23 Celltech Limited Anticorps diriges contre l'antigene carcino-embryonnaire (cea) et a greffe de zones determinant la complementarite (cdr) et production de ces anticorps

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991001990A1 (fr) * 1989-07-26 1991-02-21 City Of Hope Anticorps chimerique anti-antigene carcinoembryonique
WO1992001059A1 (fr) * 1990-07-05 1992-01-23 Celltech Limited Anticorps diriges contre l'antigene carcino-embryonnaire (cea) et a greffe de zones determinant la complementarite (cdr) et production de ces anticorps

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BEGENT, R. H. J. ET AL: "Clinical evidence of efficient tumor targeting based on single - chain Fv antibody selected from a combinatorial library", NAT. MED. (N. Y.) (1996), 2(9), 979-984, XP002128877 *
JACKSON, H. ET AL: "Antigen specificity and tumor targeting efficiency of a human carcinoembryonic antigen-specific scFv and affinity -matured derivatives", BR. J. CANCER (1998), 78(2), 181-188, XP002128798 *
OSBORNE J ET AL: "Novel super-high affinity sheep monoclonal antibodies against CEA bind colon and lung adenocarcinoma.", HYBRIDOMA, (1999 APR) 18 (2) 183-91., XP002128800 *
OSBOURN, JANE K. ET AL: "Generation of a panel of related human scFv antibodies with hig affinities for human CEA", IMMUNOTECHNOLOGY (1996), 2(3), 181-196, XP000645453 *
PIETERSZ G A ET AL: "Preclinical characterization and in vivo imaging studies of an engineered recombinant technetium-99m-labeled metallothionein-containing anti-carcinoembryonic antigen single-chain antibody.", JOURNAL OF NUCLEAR MEDICINE, (1998 JAN) 39 (1) 47-56., XP002128799 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002050120A3 (fr) * 2000-12-21 2003-04-24 Ks Biomedix Holdings Plc Anticorps hautement affinitaires
WO2002096437A1 (fr) * 2001-05-25 2002-12-05 Psimei Pharmaceuticals Plc Therapie par capture de neutrons
JP2005529612A (ja) * 2002-06-12 2005-10-06 バイエル・ヘルスケア・エルエルシー 糖化した標識の結合による細菌検査法
EP1511861A4 (fr) * 2002-06-12 2007-12-05 Genencor Int Methodes et compositions de liaison dependant du milieu d'un agent cible a une cible
EP1549759B1 (fr) * 2002-06-12 2010-04-28 Siemens Healthcare Diagnostics Inc. Methode d'essai bacteriologique par liaison d'enzymes intracellulaires

Also Published As

Publication number Publication date
IL141523A0 (en) 2002-03-10
ID28905A (id) 2001-07-12
PL346472A1 (en) 2002-02-11
GB9818915D0 (en) 1998-10-21
HRP20010149A2 (en) 2002-02-28
NO20011006D0 (no) 2001-02-27
AU5435099A (en) 2000-03-21
HUP0103233A2 (hu) 2001-12-28
JP2002525082A (ja) 2002-08-13
HUP0103233A3 (en) 2003-10-28
MXPA01002248A (es) 2002-05-08
YU15401A (sh) 2003-07-07
CA2340865A1 (fr) 2000-03-09
ZA200101573B (en) 2002-02-26
TR200100643T2 (tr) 2001-07-23
EA200100287A1 (ru) 2001-08-27
BG105294A (bg) 2001-12-29
CN1315966A (zh) 2001-10-03
EP1107990A1 (fr) 2001-06-20
NO20011006L (no) 2001-02-27
KR20010089174A (ko) 2001-09-29
BR9913303A (pt) 2001-10-09

Similar Documents

Publication Publication Date Title
Huse et al. Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda
EP0894135B1 (fr) Proteine, polyvalente et a specificites multiples, de fixation sur un antigene
JP3258630B2 (ja) 生物学的媒体中のタンパク質フラグメントの測定のためのアッセイ
JP3176917B2 (ja) 特異的結合対の構成員を製造する方法
US5837821A (en) Antibody construct
JPH06508511A (ja) 特異的な結合ペアーの構成員の製造方法
Brocks et al. Species-crossreactive scFv against the tumor stroma marker “fibroblast activation protein” selected by phage display from an immunized FAP−/− knock-out mouse
JPH02500329A (ja) ターゲット化多機能蛋白質
JP2001512560A (ja) 標的に対し特異的な親和性を有するペプチドおよびタンパク質の選択のための方法および手段
JPH03501440A (ja) 免疫反応性ヘテロ鎖抗体
WO2004081047A1 (fr) Anticorps monoclonal et hybridome produisant celui-ci
JPH06502526A (ja) 結合ドメイン
JP6731702B2 (ja) 親和性成熟化ヒト抗体の同定
Trimmer Recombinant antibodies in basic neuroscience research
WO2000012556A1 (fr) Anticorps a forte affinite
IL265995B1 (en) A ternary vector expressing antibodies in a fully therapeutic configuration
Kim et al. Expression and characterization of recombinant single-chain Fv and Fv fragments derived from a set of catalytic antibodies
JPH07506727A (ja) 凝集アッセイ用試薬
WO2004033658A2 (fr) Polypeptides catalytiques recombinants et leurs utilisations
US20030008355A1 (en) High-affinity antibodies
Zhao et al. Genetic engineering antibody: principles and application
Spooner et al. Genetically engineered antibodies for diagnostic pathology
Leow et al. Monoclonal IgY antibodies
US9518131B2 (en) Generating metal ion binding proteins
KR102511816B1 (ko) c-Myc 펩타이드 특이적인 항체 및 이의 용도

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-154/01

Country of ref document: YU

Ref document number: 99810367.5

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1999940355

Country of ref document: EP

Ref document number: IN/PCT/2001/00155/DE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 141523

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PV2001-658

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 510104

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2340865

Country of ref document: CA

Ref document number: 2340865

Country of ref document: CA

Kind code of ref document: A

Ref document number: 1999 105294

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2001/01573

Country of ref document: ZA

Ref document number: 200101573

Country of ref document: ZA

Ref document number: 1020017002434

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2001/00643

Country of ref document: TR

ENP Entry into the national phase

Ref document number: 2000 571062

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: P20010149A

Country of ref document: HR

Ref document number: PA/a/2001/002248

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 54350/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200100287

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 20010249

Country of ref document: UZ

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 09786015

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999940355

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2001-658

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1020017002434

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1999940355

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1020017002434

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV2001-658

Country of ref document: CZ